If GLP-1 Therapies Are Approved for Type 1 Diabetes, Patient Support Will Matter as Much as the Medication

For more than 100 years, nearly every major breakthrough in type 1 diabetes has focused on one...

[Webinar] The Great GLP-1 Shift: How Patient Mindset Is Reshaping Diabetes Care, Support, and Strategy

Recorded on June 24, 2026. With GLP-1 adoption rising from just 3% in 2021 to 23% in 2025,...

Patients Who Persist: What Diabetes Patient Stories Reveal About the GLP-1 Treatment Journey

Despite the widespread popularity of GLP-1 medications in the U.S., nearly three in four diabetes...

Beyond the Starts: The Hidden Moments Driving 2.1 Million GLP-1 Patient Adherence Opportunity

Explore the hidden moments that shape patient expectations, motivation, and long-term adherence in...

How Target Patients Ranked the 2026 Super Bowl Commercials for GLP-1 Drugs

The 2026 Super Bowl wasn’t just a showdown on the field, it was a battle of brands off of it. As...

How Geography and Urbanicity Are Shaping the GLP-1 Landscape

Learn why, despite consistent provider conversations across regions, our data suggests differences...

Case Study: Accelerating Nationwide Clinical Trial Recruitment for a Top 10 US Research Institution

Project Overview A top 10 US research institution was conducting a nationwide clinical trial in...

From Gut Feel to Clarity: 3 Steps to Smarter Brand Decisions

Every commercial and brand leader has experienced it: the monthly performance review where...

Don’t Let Data Blind Spots Derail Your Next KPI Meeting: A White Paper for Brand, Marketing and Product Leaders

Discover how pharma teams are closing the clarity gap with timely, defensible patient insights that...

Breaking Down Barriers: Why Are Only 31% of Type 2 Patients on GLP-1s?

GLP-1 receptor agonists such as Ozempic, Wegovy, and Mounjaro are transforming the care of type 2...